NF1 (neurofibromin 1; HGNC:7765, NCBI Gene 4763) is the gene on chromosome 17q11.2 encoding neurofibromin — the large GTPase-activating protein (GAP) that switches off RAS: it accelerates RAS-GTP's intrinsic hydrolysis hundreds-fold, converting the growth switch to its off state. Germline loss causes neurofibromatosis type 1 (one in ~3,000 births): café-au-lait spots, cutaneous and plexiform neurofibromas, optic-pathway gliomas, and skeletal dysplasia — the commonest tumor-predisposition syndrome caused by a single gene.
Approved Symbol
NF1 (HGNC:7765)
Chromosomal Locus
17q11.2
Encoded Product
Neurofibromin — a 320-kDa RAS GAP (2,839 aa) with a central GRD domain
Neurofibromatosis type 1; MEK inhibitors for plexiform neurofibromas
Gene Structure & Expression
Genomic organization: 57 exons across ~280 kb — one of the largest human genes; the GAP-related domain (GRD, exons ~21–27) carries the catalytic arginine finger; the whole gene's size explains the high de-novo-mutation rate (~half of NF1 cases are new mutations).
Expression: Broad, strongest in neurons, Schwann cells, and oligodendrocyte precursors — the cell types whose tumors define the disease; alternative splicing (type I/II transcripts differing in the GRD-adjacent exon) tunes GAP activity developmentally.
Molecular Function & Pathways
RAS regulation: Neurofibromin's GRD inserts an arginine finger into RAS-GTP, accelerating GTP hydrolysis ~100–1,000× — without it, RAS signaling (RAF-MEK-ERK and PI3K) stays lit; biallelic loss in Schwann cells drives neurofibroma formation.
Beyond RAS: cAMP regulation in neurons (the learning and attention deficits of NF1), microtubule association, and dopamine-modulatory roles — the cognitive phenotype's non-oncology biology, traced to lost cAMP control.
Clinical & Therapeutic Significance
Clinical genetics: Autosomal-dominant, full penetrance with variable expressivity; diagnostic by clinical criteria (café-au-lait macules, neurofibromas, axillary freckling, Lisch nodules, optic glioma, bone dysplasia, family history); malignant peripheral nerve sheath tumors as the life-threatening transformation.
Therapeutics: Selumetinib (MEK inhibitor) — the first approved drug for inoperable plexiform neurofibromas (~40–70% volume responses in children), working exactly where the pathway biology predicts; MEK programs continue in low-grade glioma and MPNST trials.